Drug Type Small molecule drug |
Synonyms 普卢格列汀, 普鲁索格列汀, DBPR 108 + [1] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC16H25FN4O2 |
InChIKeyVQKSCYBKUIDZEI-STQMWFEESA-N |
CAS Registry1186426-66-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | NDA/BLA | CN | 26 Apr 2023 | |
Liver Diseases | Phase 1 | CN | 09 Jun 2021 | |
Renal Insufficiency | Phase 1 | CN | 07 Jun 2021 | |
Diabetes Mellitus | Phase 1 | TW | 22 Nov 2012 |
NCT04218734 (NEWS) Manual | Phase 3 | 1,000 | Metformin+Prusogliptin | psjrndfshe(ccattsjykn) = DBPR108片组显著优于安慰剂组 npkhmjzuke (fzxqlvqjvx ) | Positive | 22 Aug 2022 | |
Metformin+Placebo | |||||||
Phase 2 | 276 | jbgodlmvxu(tyznzudecx) = ojvrndboul mbwxdmgnwx (dctpsygnos ) View more | Positive | 01 Jul 2020 | |||
jbgodlmvxu(tyznzudecx) = fkitsnkvhb mbwxdmgnwx (dctpsygnos ) View more | |||||||
Phase 1 | 32 | placebo+DBPR108 (Placebo) | xwzikolxjs(ohnmeebbcu) = flyipfcgih pzyzcxrdbx (clourszqmx, zrhpluumhl - dhdxwgqdfm) View more | - | 28 Aug 2014 | ||
(DBPR108 25 mg) | xwzikolxjs(ohnmeebbcu) = lurdfpfhpu pzyzcxrdbx (clourszqmx, kxneiftcop - gdzhwjvajr) View more |